{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:45:47Z","timestamp":1785735947152,"version":"3.56.0"},"reference-count":77,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>\n                      Despite substantial research on immunotherapy, its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC) without identifiable driver mutations remain unclear. The objective of this review was to examine the efficacy and safety of immunotherapy, used as monotherapy or alongside chemotherapy,\n                      <jats:italic>vs.<\/jats:italic>\n                      chemotherapy alone in patients with advanced driver mutation\u2013negative NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search of PubMed, Embase, Scopus, and CENTRAL databases was conducted until December 2024. The protocol was registered in PROSPERO (CRD42024585050). Randomised controlled trials (RCTs) evaluating the efficacy and safety of immunotherapy, either as monotherapy or in combination with chemotherapy, compared with chemotherapy alone, were included. A random-effects meta-analysis was performed. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the GRADE framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three RCTs (n=14605 participants) were included. Immunotherapy (\u00b1 chemotherapy) significantly improved overall survival [22 RCTs; 14,375 participants, hazard ratio (HR): 0.77; 95% Confidence interval (CI): 0.72-0.83] and progression-free survival (22 RCTs; 14,003 participants, HR: 0.67; 95% CI: 0.58-0.76) compared with chemotherapy alone. The objective response rate was also higher with immunotherapy (23 RCTs; 12,967 participants, RR 1.38, 95% CI: 1.24-1.54). No statistically significant differences were observed between the groups in terms of overall adverse event rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation and conclusions<\/jats:title>\n                    <jats:p>Immunotherapy, whether administered alone or in combination with chemotherapy, provides significant survival benefits in patients with advanced driver mutation\u2013negative NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijmr_3200_2025","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:47:21Z","timestamp":1785700041000},"page":"203-219","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis"],"prefix":"10.25259","volume":"164","author":[{"given":"Jogender","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvadeep","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Raghav","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Meena","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdish Prasad","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, All India Institute of Medical Science, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaivinder","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Advanced Pediatrics Centre), Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"10.25259\/IJMR_3200_2025\/ref-1","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"10.25259\/IJMR_3200_2025\/ref-2","doi-asserted-by":"crossref","first-page":"132839","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: A molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res."},{"key":"10.25259\/IJMR_3200_2025\/ref-4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/cancers14010122","article-title":"Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectives","volume":"14","author":"De Mello","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.25259\/IJMR_3200_2025\/ref-5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/14737140.2022.2116005","article-title":"Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced NSCLC: An updated systematic review and meta-analysis","volume":"22","author":"Abdelazeem","year":"2022","journal-title":"Expert Rev Anticancer Ther."},{"key":"10.25259\/IJMR_3200_2025\/ref-6","doi-asserted-by":"publisher","first-page":"100465","DOI":"10.1016\/j.esmoop.2022.100465","article-title":"Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Siciliano","year":"2022","journal-title":"ESMO Open."},{"key":"10.25259\/IJMR_3200_2025\/ref-7","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1111\/1759-7714.14664","article-title":"Immunotherapy combined with chemotherapy versus chemotherapy alone in PD-L1-negative advanced nonsquamous NSCLC","volume":"13","author":"Chai","year":"2022","journal-title":"Thorac Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/jcm11061655","article-title":"Combined immunotherapy with chemotherapy versus bevacizumab with chemotherapy in first-line treatment of driver-gene-negative non-squamous non-small cell lung cancer: An updated systematic review and network meta-analysis","volume":"11","author":"Chai","year":"2022","journal-title":"JCM."},{"key":"10.25259\/IJMR_3200_2025\/ref-9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous NSCLC: 5-year update of KEYNOTE-407","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-10","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous NSCLC: 5-year outcomes from KEYNOTE-189","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-12","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial","volume":"211","author":"Reck","year":"2024","journal-title":"Eur J Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-13","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2024"},{"key":"10.25259\/IJMR_3200_2025\/ref-14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.25259\/IJMR_3200_2025\/ref-15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"10.25259\/IJMR_3200_2025\/ref-16","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.eclinm.2024.102691","article-title":"PeRinatal, neOnatal, and Maternal OuTcomEs with azithromycin prophylaxis in pregnancy and labour (PROMOTE-PROPHYLAXIS): Systematic review and meta-analysis","volume":"73","author":"Shamim","year":"2024","journal-title":"EClinicalMedicine."},{"key":"10.25259\/IJMR_3200_2025\/ref-17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE working group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"J Clin Epidemiol."},{"key":"10.25259\/IJMR_3200_2025\/ref-18","doi-asserted-by":"publisher","first-page":"e008189","DOI":"10.1136\/jitc-2023-008189","article-title":"Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial","volume":"12","author":"Carbone","year":"2024","journal-title":"J Immunother Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10147-022-02120-0","article-title":"Asian subanalysis of CheckMate 9LA","volume":"27","author":"John","year":"2022","journal-title":"Int J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"CheckMate 9LA phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"Three-year update of CheckMate 9LA","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejca.2023.01.015","article-title":"CheckMate 9LA patient-reported outcomes","volume":"183","author":"Reck","year":"2023","journal-title":"Eur J Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-23","doi-asserted-by":"publisher","first-page":"100273","DOI":"10.1016\/j.esmoop.2021.100273","article-title":"CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open."},{"key":"10.25259\/IJMR_3200_2025\/ref-24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/cas.14817","article-title":"IMpower132 Japanese cohort","volume":"112","author":"Nishio","year":"2021","journal-title":"Cancer Sci."},{"key":"10.25259\/IJMR_3200_2025\/ref-25","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.esmoop.2022.100394","article-title":"CheckMate 227 Asian subpopulation","volume":"7","author":"O\u2019Byrne","year":"2022","journal-title":"ESMO Open."},{"key":"10.25259\/IJMR_3200_2025\/ref-26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"Four-year outcomes of CheckMate 227","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-27","doi-asserted-by":"publisher","first-page":"102065","DOI":"10.1016\/j.esmoop.2023.102065","article-title":"Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: Results of the phase III CheckMate 227 Part 2 trial","volume":"8","author":"Borghaei","year":"2023","journal-title":"ESMO Open."},{"key":"10.25259\/IJMR_3200_2025\/ref-28","doi-asserted-by":"publisher","first-page":"2093104","DOI":"10.1056\/nejmoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-29","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV NSCLC","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-30","doi-asserted-by":"crossref","first-page":"165769","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-31","doi-asserted-by":"crossref","first-page":"204051","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-32","doi-asserted-by":"crossref","first-page":"150517","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"JCO."},{"key":"10.25259\/IJMR_3200_2025\/ref-33","doi-asserted-by":"crossref","first-page":"207892","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-34","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1111\/cas.14980","article-title":"Pembrolizumab plus pemetrexed\u2013platinum for metastatic nonsquamous NSCLC: KEYNOTE-189 Japan study","volume":"112","author":"Horinouchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.25259\/IJMR_3200_2025\/ref-35","doi-asserted-by":"crossref","first-page":"88195","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: Protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-36","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1111\/cas.15144","article-title":"First-line pembrolizumab versus chemotherapy in metastatic NSCLC: KEYNOTE-024 Japan subset","volume":"112","author":"Satouchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.25259\/IJMR_3200_2025\/ref-37","doi-asserted-by":"crossref","first-page":"53746","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"JCO."},{"key":"10.25259\/IJMR_3200_2025\/ref-38","doi-asserted-by":"crossref","first-page":"18233","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-39","doi-asserted-by":"crossref","first-page":"23394","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer With PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"JCO."},{"key":"10.25259\/IJMR_3200_2025\/ref-40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.lungcan.2018.08.019","article-title":"Pembrolizumab and platinum-based chemotherapy: Phase 1 KEYNOTE-021","volume":"125","author":"Gadgeel","year":"2018","journal-title":"Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2018.08.004","article-title":"Twenty-four-month overall survival from KEYNOTE-021 cohort G","volume":"14","author":"Borghaei","year":"2019","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-43","doi-asserted-by":"publisher","first-page":"1497508","DOI":"10.1016\/s1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-44","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013expressing NSCLC: KEYNOTE-042","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet."},{"key":"10.25259\/IJMR_3200_2025\/ref-45","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Pembrolizumab versus chemotherapy in Chinese patients with PD-L1\u2013positive NSCLC","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-46","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Extended follow-up of CameL trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus chemotherapy in advanced nonsquamous NSCLC (CameL)","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-48","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus chemotherapy in squamous NSCLC (CameL-Sq)","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-49","first-page":"1","article-title":"Efficacy of camrelizumab in advanced NSCLC","volume":"2022","author":"Zou","year":"2022","journal-title":"J Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2023.01.013","article-title":"NEPTUNE China cohort","volume":"178","author":"Cheng","year":"2023","journal-title":"Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2022.09.223","article-title":"NEPTUNE phase 3 trial","volume":"18","author":"De Castro","year":"2023","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-52","doi-asserted-by":"publisher","first-page":"107422","DOI":"10.1016\/j.lungcan.2023.107422","article-title":"Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)","volume":"186","author":"Garon","year":"2023","journal-title":"Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-53","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cllc.2024.03.003","article-title":"Outcomes by PD-L1 expression in POSEIDON","volume":"25","author":"Garon","year":"2024","journal-title":"Clin Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-54","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab plus chemotherapy: POSEIDON","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-55","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"MYSTIC trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cllc.2021.02.010","article-title":"Patient-reported outcomes from MYSTIC","volume":"22","author":"Garon","year":"2021","journal-title":"Clin Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-57","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy: EMPOWER-Lung 3","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-58","doi-asserted-by":"publisher","first-page":"107821","DOI":"10.1016\/j.lungcan.2024.107821","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 \u2265 1%: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial","volume":"193","author":"Baramidze","year":"2024","journal-title":"Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-59","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy in NSCLC","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-60","doi-asserted-by":"publisher","first-page":"92437","DOI":"10.1016\/s1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-61","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/cam4.5144","article-title":"IMpower132 China cohort","volume":"12","author":"Lu","year":"2023","journal-title":"Cancer Med."},{"key":"10.25259\/IJMR_3200_2025\/ref-62","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"IMpower132 randomized trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-63","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"IMpower110 overall survival","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-64","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Ipilimumab with chemotherapy in squamous NSCLC","volume":"35","author":"Govindan","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-65","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"GEMSTONE-302 trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-66","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"RATIONALE-304 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-67","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"ORIENT-11 updated overall survival","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-68","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","article-title":"Final ORIENT-11 overall survival","volume":"171","author":"Zhang","year":"2022","journal-title":"Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-69","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Sintilimab plus chemotherapy in ORIENT-11","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-70","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/PPO.0000000000000583","article-title":"Tislelizumab plus chemotherapy and quality of life","volume":"28","author":"Lu","year":"2022","journal-title":"Cancer J."},{"key":"10.25259\/IJMR_3200_2025\/ref-72","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s10147-023-02390-2","article-title":"Five-year outcomes of CheckMate 227 in Japan","volume":"28","author":"Nishio","year":"2023","journal-title":"Int J Clin Oncol."},{"key":"10.25259\/IJMR_3200_2025\/ref-73","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cllc.2024.03.003","article-title":"Durvalumab with or without tremelimumab plus chemotherapy: PD-L1 subgroup analysis of POSEIDON","volume":"25","author":"Garon","year":"2024","journal-title":"Clin Lung Cancer."},{"key":"10.25259\/IJMR_3200_2025\/ref-74","doi-asserted-by":"publisher","first-page":"948597","DOI":"10.3389\/fimmu.2022.948597","article-title":"A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer","volume":"13","author":"Shao","year":"2022","journal-title":"Front Immunol."},{"key":"10.25259\/IJMR_3200_2025\/ref-75","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.21037\/tlcr-21-15","article-title":"First-line immunotherapy in NSCLC with poor performance status","volume":"10","author":"Facchinetti","year":"2021","journal-title":"Transl Lung Cancer Res."},{"key":"10.25259\/IJMR_3200_2025\/ref-76","doi-asserted-by":"publisher","first-page":"100644","DOI":"10.1016\/j.drup.2019.100644","article-title":"Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer","volume":"46","author":"Leonetti","year":"2019","journal-title":"Drug Resist Updat."},{"key":"10.25259\/IJMR_3200_2025\/ref-77","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term survival with dual immune checkpoint blockade","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol."}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/efficacy-and-safety-of-immunotherapy-in-driver-mutation-negative-advanced-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/efficacy-and-safety-of-immunotherapy-in-driver-mutation-negative-advanced-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:24:48Z","timestamp":1785734688000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/efficacy-and-safety-of-immunotherapy-in-driver-mutation-negative-advanced-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":77,"alternative-id":["10.25259\/IJMR_3200_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_3200_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"203"}}